Johnson & Johnson completed its $1 billion Firefly Bio acquisition, strengthening its oncology pipeline and targeted cancer therapies.
Kimberly Redmond is a reporter at NJBIZ. With over 15 years of experience, she covers a range of topics including New Jersey's retail, cannabis, hospitality, and food industries, while also delving into business and economics. Kimberly's work has been featured in Long Island Business News, CDC Gaming Reports, Finance & Commerce, The Daily Record, NJBIZ, and NewsBreak.













